凝血酶市場規模、佔有率及成長分析（依產品、劑型、最終用戶及地區分類）－2026-2033年產業預測

預計到 2024 年，全球凝血酶市場規模將達到 6.6296 億美元，到 2025 年將達到 6.9942 億美元，到 2033 年將達到 10.734 億美元，預測期（2026-2033 年）的複合年成長率為 5.5%。

由於凝血酶在止血和血液凝固中發揮重要作用，尤其是在外科手術和創傷護理中，全球凝血酶市場正經歷顯著成長。心血管和整形外科手術數量的增加以及人口老化是推動市場需求的關鍵因素。重組凝血酶等創新技術提高了產品的安全性和有效性，同時解決了與動物性產品相關的擔憂。生物技術和製藥領域（例如再生醫學和創傷治療）的不斷擴展的應用也支持市場發展。北美憑藉其先進的醫療保健基礎設施和有利的報銷政策引領市場，其次是歐洲。亞太地區的新興市場，特別是中國和印度，儘管面臨高昂的製造成本和監管障礙等挑戰，預計仍將實現顯著成長。

全球凝血酶市場促進因素

全球對凝血酶產品的需求主要受外科手術數量不斷增加的驅動，而外科手術數量的增加主要是由於人口老化以及心血管疾病和癌症等非傳染性疾病的增加。在每年全球數百萬例外科手術中，凝血酶在約65%的心血管手術和55%的整形外科手術中發揮關鍵作用，作為主要的局部止血劑來控制出血。此外，微創手術的日益普及進一步增加了對有效止血解決方案（如凝血酶）的需求，這些解決方案能夠快速有效地控制出血，從而確保手術成功。

限制全球凝血酶市場的因素

全球凝血酶市場面臨許多限制因素，尤其是重組凝血酶的高成本。這項先進的生物技術生產的產品價格昂貴，限制了其供應和使用，尤其是在發展中地區經濟拮据的醫療機構。由於這些機構傾向於選擇價格較低的止血劑，高昂的生產成本成為市場滲透和廣泛應用的障礙。因此，許多醫療機構面臨的經濟壓力限制了凝血酶產品在最需要的地方有效利用。

全球凝血酶市場趨勢

隨著人們對更安全、更純淨的傳統牛凝血酶替代品的需求日益成長，全球凝血酶市場正經歷著向重組凝血酶產品的重大轉變。這項轉變的驅動力主要來自外科手術領域，尤其是醫療保健領域對可靠止血劑需求的不斷成長，因為微創手術技術需要精準有效的止血。此外，生物技術的進步和病人安全意識的提高也促進了重組產品的廣泛應用，使其逐漸成為醫療專業人員和醫療機構的首選。因此，這一趨勢有可能重塑凝血酶市場的競爭格局。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 顧客購買行為分析

全球凝血酶市場規模（依產品類型及複合年成長率分類）（2026-2033 年）

• 牛凝血酶
• 人類凝血酶
• 重組凝血酶

全球凝血酶市場規模（依劑型分類）及複合年成長率（2026-2033 年）

• 粉末
• 溶液劑型

全球凝血酶市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 診斷中心
• 研究所

全球凝血酶市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Baxter International Inc.
• Shanghai RAAS Blood Products Co. Ltd.
• GE Healthcare
• Bayer AG
• CSL Behring
• Grifols
• Hualan Biological Engineering
• Haematologic Technologies Inc.
• Octapharma AG
• Omrix Biopharmaceuticals Ltd.
• Japan Blood Products Organization
• Mallinckrodt Pharmaceuticals
• Mochida Pharmaceutical Co. Ltd.

結論與建議

Global Thrombin Market size was valued at USD 662.96 Million in 2024 and is poised to grow from USD 699.42 Million in 2025 to USD 1073.4 Million by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The global thrombin market is experiencing significant growth, driven by its essential role in hemostasis and blood coagulation, particularly within surgical and trauma settings. Increasing surgical procedures in areas like cardiovascular and orthopedic surgery, along with a rising elderly population, are key factors propelling market demand. Innovations, including recombinant thrombin, have improved product safety and efficacy while addressing concerns associated with animal-derived products. The market is further supported by expanding applications in biotechnology and pharmaceuticals, such as regenerative medicine and wound healing. North America leads the market due to its advanced healthcare infrastructure and favorable reimbursement policies, while Europe follows closely. Emerging markets in Asia-Pacific, particularly China and India, are poised for substantial growth, despite challenges from high manufacturing costs and regulatory hurdles.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Thrombin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Thrombin Market Segments Analysis

Global Thrombin Market is segmented by Product, Dosage Form, End-User and region. Based on Product, the market is segmented into Bovine Thrombin, Human Thrombin and Recombinant Thrombin. Based on Dosage Form, the market is segmented into Powder Form and Solution Form. Based on End-User, the market is segmented into Hospitals, Diagnostic Centers and Research Institutions. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Thrombin Market

The global demand for thrombin products is significantly driven by the rising number of surgical procedures, largely attributed to an ageing population and the increasing prevalence of non-communicable diseases such as cardiovascular disorders and cancer. With millions of surgical interventions conducted worldwide annually, thrombin plays a critical role in approximately 65% of cardiovascular surgeries and 55% of orthopedic operations, serving as a key local hemostatic agent to control bleeding. Additionally, the trend towards minimally invasive surgeries emphasizes the necessity for effective hemostatic solutions like thrombin, which ensures successful surgical outcomes by facilitating timely and skilled bleeding management.

Restraints in the Global Thrombin Market

The global thrombin market faces significant constraints due to the high costs associated with producing thrombin, particularly recombinant thrombin. This advanced biotechnology results in expensive products, which can limit their availability and usage, especially in economically challenged healthcare facilities in developing regions. As these facilities often opt for more affordable hemostatic alternatives, the high production costs create a barrier to market penetration and widespread application. Consequently, the financial constraints faced by many healthcare providers hinder the potential for thrombin products to be utilized effectively in settings where they are most needed.

Market Trends of the Global Thrombin Market

The global thrombin market is witnessing a significant shift towards recombinant thrombin products, reflecting an increasing preference for safer and purer alternatives to traditional bovine-source thrombin. This shift is being propelled by the rising demand for reliable hemostatic agents in surgical settings, particularly as the healthcare sector embraces minimally invasive techniques that require precise and effective hemostasis. Additionally, advancements in biotechnology and heightened awareness regarding patient safety are contributing to the growing adoption of recombinant options, positioning them as the preferred choice among healthcare professionals and institutions. Consequently, this trend is poised to reshape the competitive landscape of the thrombin market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Thrombin Market Size by Product & CAGR (2026-2033)

• Market Overview
• Bovine Thrombin
• Human Thrombin
• Recombinant Thrombin

Global Thrombin Market Size by Dosage Form & CAGR (2026-2033)

• Market Overview
• Powder Form
• Solution Form

Global Thrombin Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Centers
• Research Institutions

Global Thrombin Market Size & CAGR (2026-2033)

• North America (Product, Dosage Form, End-User)
  • US
  • Canada
• Europe (Product, Dosage Form, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Dosage Form, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Dosage Form, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Dosage Form, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haematologic Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omrix Biopharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Japan Blood Products Organization
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mochida Pharmaceutical Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations